Physician profile
Eric L Bohn
NPI 1811989320
$9,226.80
in general payments reported to CMS, 2019-2025
48 companies · $859 in 2025
The $859 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,382 · 2020: $1,668 · 2021: $1,580 · 2022: $1,806 · 2023: $1,153 · 2024: $779 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,540.17 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,103.86 | 2019-2025 | Vraylar, Ubrelvy, Qulipta |
| Pfizer INC. | $900.57 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $636.60 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $579.25 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $500.42 | 2019-2025 | Otezla, Repatha, Repatha |
| Amarin Pharma, INC. | $401.32 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $358.30 | 2019-2023 | Trintellix |
| Sanofi-Aventis U.S. LLC | $314.50 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.74 | 2019-2025 | Ofev |
| Otsuka America Pharmaceutical, INC. | $290.86 | 2019-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $255.70 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $254.86 | 2019-2024 | Gardasil 9, Gardasil, M-M-R II |
| Eisai INC. | $157.09 | 2020-2025 | |
| Rhythm Pharmaceuticals, INC. | $154.71 | 2022-2025 | Imcivree, Imcivree |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Bohn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.